Did you get your copy of the
FenceBuilder Newsletter?

View the latest Fence Builder Newsletter

View all Past Issues here

potflagsThe debate around cannabis legalisation in France remains a contentious issue, with growing public and political interest. Among the voices opposing this shift is the French Academy of Medicine, which has reinforced its steadfast stance against the legalisation of recreational cannabis. Citing robust evidence from other nations that have adopted legalisation, the Academy highlights significant public health risks and underscores the importance of prevention and education.

Public Health Risks Highlighted by the Academy of Medicine

The Academy of Medicine firmly believes that the legalisation of recreational cannabis poses significant health challenges. It recently released a formal statement affirming its opposition, supported by the latest evidence-based studies.

One of the Academy’s primary concerns lies in the impact of cannabis legalisation on road safety. A pivotal Canadian study, published in 2022 in the New England Journal of Medicine, highlighted alarming figures. After cannabis was legalised in Canada, the proportion of motorists hospitalised after accidents who tested positive for tetrahydrocannabinol (THC)—cannabis’s main active ingredient—doubled. This data paints a worrying picture of the potential risks on French roads if cannabis use is legalised.

Another area of concern is mental health. The Academy cited another Canadian study published in the JAMA Network Open in 2025. This research revealed that cannabis-associated schizophrenia cases among hospitalised patients nearly tripled after legalisation. These findings align with the Academy’s emphasis on prioritising public well-being over recreational freedoms.

The French Academy of Medicine has reiterated that legalising recreational cannabis would be a “serious health error.” In a press release, the Academy emphasised that cannabis use is associated with significant risks, including impaired cognitive function, addiction, and mental health disorders. It also highlighted the lack of sufficient evidence to support claims of cannabis’s safety when used recreationally.

Lessons from Legalisation Elsewhere

Countries like Canada and certain US states have become key testing grounds for understanding the consequences of cannabis legalisation. By assessing their experiences, France has a valuable opportunity to evaluate potential risks before implementing similar laws.

Specifically, Canada’s legalisation has served as a cautionary tale, providing evidence of issues such as increased substance misuse and negative health outcomes. These findings are critical as discussions surrounding cannabis legalisation in France gain momentum. Instead of rushing into premature reforms, the Academy urges policymakers to carefully evaluate these findings to safeguard the nation’s health.

Prevention Over Legalisation

The Academy strongly advocates for maintaining the ban on cannabis use and sale in France. The primary focus must be on educating the public, particularly young people, on the potential risks of cannabis consumption.

Investing in comprehensive prevention programmes that include schools, families, and community outreach could reduce demand. The institution insists that well-executed prevention efforts would achieve better results in reducing cannabis misuse than legalisation would.

Cannabis Legalisation in France and the Political Context

The Academy’s renewed opposition to cannabis legalisation comes at a time of growing political discussion on the topic. Recent proposals have suggested a tightly controlled legalisation framework, but these discussions fail to address the significant health concerns raised by experts. The French Academy of Medicine believes that cautious policymaking informed by existing evidence is crucial to safeguarding the nation’s health.

Instead of adopting measures that echo the mistakes of other nations, France has the opportunity to reinforce its commitment to public health. By rejecting legalisation and strengthening prevention efforts, the country can mitigate the risks associated with cannabis use while fostering greater awareness about its consequences.

(Source: WRD News)

Featured Website

World Federation Against Drugs

World Federation Against Drugs (W.F.A.D) Dalgarno Institute is a member of this global initiative. For evidence based data on best practice drug policy in the global context.
Featured Website
Alt Tag

Institute for Behavior and Health

The Institute for Behavior and Health, Inc. is to reduce the use of illegal drugs. We work to achieve this mission by conducting research, promoting ideas that are affordable and scalable...
Featured Website

Drug Free Australia

Drug Free Australia Website. Drug Free Australia is a peak body, representing organizations and individuals who value the health and wellbeing of our nation...
Featured Website

Drug Advisory Council of Australia (D.A.C.A)

Drug Advisory Council of Australia (D.A.C.A) Dalgarno Institute is an executive member of this peak body. For updates on current illicit drug issues.
Featured Website

International Task Force on Strategic Drug Policy

(I.T.F.S.D.P) This international peak body continues to monitor and influence illicit drug policy on the international stage. Dalgarno Institute is a member organisation.
Featured Website

Smart Approaches to Marijuana

Smart Approaches to Marijuana. SAM's leaders are among the world's most prominent voices calling for science-based marijuana education and awareness.

21 Be There

There isn’t merely data sharing - it isn't about promoting a 'one dimensional' legislative solution to a complex problem
Featured Website

Drug Free Futures

Drug Policy Futures believes in engaging in an open dialogue about the strengths and weaknesses of global drug policies...
Featured Website

Action Alcohol

The National Alliance for Action on Alcohol is a national coalition of health and community organisations from across Australia that has been formed with the goal of reducing alcohol-related harm.
Featured Website

Greater Risk

Greater Risk Website - The younger they start the greater the risk...
Featured Website

Rivermend Health

RiverMend Health is a premier provider of scientifically driven, specialty behavioral health services to those suffering from alcohol and drug dependency, dual disorders, eating disorders, obesity and chronic pain.
Featured Website

Evidence-Based Practices Resource Center

SAMHSA is committed to improving prevention, treatment, and recovery support services for mental and substance use disorders.
Featured Website

SAMHSA

SAMHSA is committed to improving prevention, treatment, and recovery support services for mental and substance use disorders.